knowledge -WSS

knowledge

author：entertainment 2025-09-27 22:18:10 - browse：8

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： CDC: Cases of alpha

focus

WSS

Alexander Hamilton and the argument for universal insurance

Public health communication lessons from Covid

Hospitals, health systems can help patients avoid medical debt

How digital tools helped lower hypertension in marginalized patients

Marc Tessier

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

focus

knowledge

focus

Psychedelics group wrestles with new pharma identity

CDC: Cases of alpha

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Medical records are filled with copy

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

Duchenne breakthrough therapy leaves behind pioneering families

What we’ve learned from the Aduhelm mess

The cancer drug shortage isn’t new — and neither are the solutions

What we’ve learned from the Aduhelm mess

hotspot

Trump allegedly attempted to have surveillance video deleted: Special Counsel

Doctors' information doesn't help them choose wisely when sick

Private equity deals in Medicare Advantage declines

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Hospitals, health systems can help patients avoid medical debt

Doctors' information doesn't help them choose wisely when sick

hotspot

leisure time

focus

explore